Table 3.
Sensitivity analyses of benign tumor risk estimates (all sites combined) comparing myotonic dystrophy type I (DM1)‐affected patients with DM1‐free controls.
| Sensitivity analysis1 | Number of patients with tumor/Total | HR | 95% CI | P‐value | ||
|---|---|---|---|---|---|---|
| DM1 | DM1‐free | |||||
| 1 | 71/454 | 362/5936 | 1.65 | 1.22 | 2.23 | 0.001 |
| 2 | 55/376 | 332/5541 | 1.25 | 0.89 | 1.75 | 0.19 |
| 3 | 72/530 | 383/6988 | 1.55 | 1.16 | 2.08 | 0.004 |
| 4 | 42/927 | 364/13,085 | 1.98 | 1.35 | 2.89 | <0.001 |
1
Analyses: (1) Restricted to DM1 patients diagnosed after their clinic's “up to standard” date and their matched cohort. (2) Restricted to DM1 patients with DM1 records in at least two data sources and their matched cohort. (3) Restricted to DM1 patients diagnosed in 1995 or later and their matched cohort. (4) Ending follow‐up at a maximum of 3 years for both cohorts.